AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Apptly Health Technologies Corp.

$0.08 -$0.03 (-27.09%)
OTC · 14 Sep 2026 20:00 UTC
Previous Close
$0.08
Day Range
$0.08$0.08
Year Range
$0.03$0.38
Market Cap
527.4K
AVG Volume
1.65K
Trailing/Forward PE
-1.53/-
PEG ratio
-0
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
Other OTCUS
Revenue (CAD)
050K100K150K2019202020212022202320242025
ESVNF Revenue (CAD) by year
PeriodRevenue (CAD)
2025121.75K
20240
20230
20220
20210
20200
20190
Net Income (CAD)
-15M-10M-5M02019202020212022202320242025
ESVNF Net Income (CAD) by year
PeriodNet Income (CAD)
2025-7.2M
2024-598.16K
2023-12.49M
2022-5.54M
2021-3.28M
2020-2.56M
2019-66.05K
Operating Income (CAD)
-6M-4M-2M02019202020212022202320242025
ESVNF Operating Income (CAD) by year
PeriodOperating Income (CAD)
2025-5.63M
2024-506.32K
2023-1.18M
2022-2.51M
2021-3.2M
2020-2.37M
2019-66.05K
EBITDA (CAD)
-6M-4M-2M02M2019202020212022202320242025
ESVNF EBITDA (CAD) by year
PeriodEBITDA (CAD)
2025-5.13M
2024-636.07K
2023288.62K
2022-17.37K
2021-3.05M
2020-1.28M
2019-9.31K
Cash Flows (CAD)
-6M-4M-2M02019202020212022202320242025
ESVNF Cash Flows (CAD) by year
PeriodCash Flows (CAD)
2025-2.03M
2024-664.84K
2023-1.66M
2022-3.94M
2021-5.03M
2020-1.88M
2019-31.23K
EPS (CAD)
-0.2-0.15-0.1-0.05-02019202020212022202320242025
ESVNF EPS (CAD) by year
PeriodEPS (CAD)
2025-0.07
2024-0.01
2023-0.2
2022-0.09
2021-0.05
2020-0.07
2019-0.01
Expenses (CAD)
02M4M6MSG&ACapex2019202020212022202320242025
ESVNF Expenses (CAD) by year
PeriodExpenses (CAD)
20253.92M
2024366.24K
2023727.14K
20224.35M
20215.47M
20202.6M
201966.05K
Cash & Debt (CAD)
02.5M5M7.5M10MCashLong Term DebtShort Term Debt2019202020212022202320242025
ESVNF Cash & Debt (CAD) by year
PeriodCash & Debt (CAD)
2025704K
20241.72M
20232.39M
20224.05M
20218.06M
20204.7M
2019190.62K
Debt ratios
-0.500.512022202320242025
ESVNF Debt ratios by year
PeriodDebt ratios
2025-0.28
20240.5
20230.59
20220.93
Margins
-1500%-1000%-500%0%2025
ESVNF Margins by year
PeriodMargins
2025-1406.75%
Return on Capital
-600%-400%-200%0%200%400%2019202020212022202320242025
ESVNF Return on Capital by year
PeriodReturn on Capital
2025257.33%
2024-33.35%
2023-522.02%
2022-37.25%
2021-16.54%
2020-19.14%
2019-28.42%
Shares Outstanding
020M40M60M80M2019202020212022202320242025
ESVNF Shares Outstanding by year
PeriodShares Outstanding
202561.79M
202465.11M
202365.11M
202265.11M
202165.11M
202055.79M
20197.44M
Book Value Per Share (CAD)
-0.100.10.20.30.42019202020212022202320242025
ESVNF Book Value Per Share (CAD) by year
PeriodBook Value Per Share (CAD)
2025-0.05
20240.03
20230.04
20220.23
20210.3
20200.24
20190.03
Total Assets (CAD)
010M20M30M2019202020212022202320242025
ESVNF Total Assets (CAD) by year
PeriodTotal Assets (CAD)
2025934.84K
20242.28M
20232.49M
202215.24M
202120.94M
202013.7M
2019281.42K
PE Ratio
3.363.383.43.423.44med 3.41Jun 26Jun 26Jul 26Jul 26
ESVNF PE Ratio by year
PeriodPE Ratio
Jul 263.4
Jul 263.39
Jul 263.42
Jul 263.42
Jun 263.43
Jun 263.41
Jun 263.38
Jun 263.37
Free Cash Flow Yield
-300%-200%-100%0%med -57.52%Nov 24Feb 25Jun 25Sep 25Jan 26Jun 26Sep 26
ESVNF Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Sep 26-29.19%
Sep 26-28.83%
Sep 26-24.95%
Aug 26-20.01%
Aug 26-23.81%
Aug 26-57.65%
Aug 26-57.39%
Jul 26-57.07%
Jul 26-183.61%
Jul 26-184.56%
Jul 26-182.85%
Jul 26-182.46%
Jun 26-182.37%
Jun 26-183.03%
Jun 26-184.98%
Jun 26-185.65%
Apr 26-178.38%
Apr 26-177.76%
Apr 26-244.03%
Mar 26-31.48%
Mar 26-76.91%
Mar 26-69.07%
Mar 26-69.89%
Feb 26-69.49%
Feb 26-69.31%
Feb 26-69.61%
Feb 26-69.33%
Jan 26-69.6%
Jan 26-59.44%
Jan 26-58.52%
Jan 26-58.53%
Jan 26-59.31%
Dec 25-59.55%
Dec 25-59.01%
Dec 25-59.13%
Dec 25-58.94%
Nov 25-58.28%
Nov 25-57.75%
Nov 25-58.08%
Nov 25-57.97%
Oct 25-58.15%
Oct 25-6.57%
Oct 25-6.56%
Oct 25-6.57%
Oct 25-6.59%
Sep 25-6.59%
Sep 25-6.67%
Sep 25-6.64%
Sep 25-6.65%
Aug 25-6.69%
Aug 25-6.65%
Aug 25-6.65%
Aug 25-6.68%
Aug 25-6.67%
Jul 25-8.46%
Jul 25-8.45%
Jul 25-8.47%
Jul 25-8.54%
Jun 25-8.48%
Jun 25-8.44%
Jun 25-8.54%
Jun 25-8.47%
May 25-8.44%
May 25-8.45%
May 25-8.3%
May 25-8.32%
May 25-8.39%
Apr 25-12.1%
Apr 25-13.46%
Apr 25-13.43%
Apr 25-13.09%
Mar 25-13.01%
Mar 25-12.97%
Mar 25-12.96%
Mar 25-9.82%
Feb 25-9.75%
Feb 25-11.09%
Feb 25-11.67%
Feb 25-11.91%
Jan 25-11.72%
Jan 25-12.32%
Jan 25-9.38%
Jan 25-10.52%
Jan 25-105.01%
Dec 24-151.8%
Dec 24-152.22%
Dec 24-148.04%
Dec 24-105.42%
Nov 24-157.76%
Nov 24-248.58%
Nov 24-241.08%
Nov 24-163.62%
Nov 24-271.89%
Oct 24-133.83%
Oct 24-171.51%
Oct 24-84.63%
Oct 24-85.79%
Sep 24-86.17%
Sep 24-85.83%
Sep 24-85.72%
Price to Sales
20406080100med 57.36Aug 26Aug 26Sep 26Sep 26
ESVNF Price to Sales by year
PeriodPrice to Sales
Sep 2657.01
Sep 2657.72
Sep 2666.69
Aug 2683.15
Aug 2669.88
Aug 2628.87
Aug 2629
Jul 2629.16
EV/EBITDA
-50510med -1.61Nov 23Jan 24Feb 24Apr 24Jul 24Sep 24Oct 24
ESVNF EV/EBITDA by year
PeriodEV/EBITDA
Oct 24-3.96
Oct 24-4.91
Oct 24-1.46
Oct 24-1.55
Sep 24-1.58
Sep 24-1.56
Sep 24-1.55
Sep 24-4.97
Aug 24-4.99
Aug 24-4.98
Aug 24-4.29
Aug 24-3.88
Aug 24-3.83
Jul 24-2.74
Jul 24-2.75
Jun 24-0.98
Jun 24-2.29
May 24-1.93
May 24-2.3
May 24-2.3
Apr 24-1.29
Apr 24-1.17
Apr 24-1.79
Mar 24-1.78
Mar 24-1.99
Mar 24-2.04
Mar 24-1.61
Feb 24-0.89
Feb 24-1.62
Feb 24-1.37
Feb 24-1.57
Feb 24-1.38
Jan 24-4.23
Jan 24-0.64
Jan 24-0.66
Jan 24-0.85
Dec 23-0.92
Dec 23-0.48
Dec 23-0.4
Dec 232.51
Dec 236.93
Nov 23-4.79
Nov 23-4.75
Nov 234.67
Nov 232.13
Price to Book
02468med 0.66Sep 24Jan 25Apr 25Aug 25Nov 25Feb 26Jul 26
ESVNF Price to Book by year
PeriodPrice to Book
Jul 260.18
Jul 260.18
Jul 260.18
Jul 260.18
Jun 260.18
Jun 260.18
Jun 260.18
Jun 260.18
Apr 260.21
Apr 260.21
Apr 260.16
Mar 261.21
Mar 260.49
Mar 260.55
Mar 260.54
Feb 260.55
Feb 260.55
Feb 260.55
Feb 260.55
Jan 260.55
Jan 260.65
Jan 260.66
Jan 260.66
Jan 260.65
Dec 250.65
Dec 250.65
Dec 250.65
Dec 250.65
Nov 250.66
Nov 250.67
Nov 250.66
Nov 250.66
Oct 250.66
Oct 255.64
Oct 255.65
Oct 255.64
Oct 255.62
Sep 255.62
Sep 255.55
Sep 255.58
Sep 255.57
Aug 255.54
Aug 255.57
Aug 255.57
Aug 255.55
Aug 255.56
Jul 255
Jul 255
Jul 254.99
Jul 254.95
Jun 254.99
Jun 255.01
Jun 254.95
Jun 254.99
May 255.01
May 255.01
May 255.09
May 255.08
May 255.04
Apr 254.76
Apr 254.28
Apr 254.29
Apr 254.4
Mar 254.43
Mar 254.44
Mar 254.44
Mar 255.86
Feb 255.9
Feb 255.19
Feb 254.93
Feb 254.83
Jan 254.91
Jan 255.4
Jan 257.1
Jan 256.33
Jan 250.63
Dec 240.44
Dec 240.44
Dec 240.45
Dec 240.63
Nov 240.42
Nov 240.27
Nov 240.28
Nov 240.41
Nov 240.24
Oct 240.52
Oct 240.41
Oct 240.82
Oct 240.81
Sep 240.81
Sep 240.81
Sep 240.81
Sep 240.4
Aug 240.4
Aug 240.4
Aug 240.48
Aug 240.53
Aug 240.54
Jul 240.09
Jul 240.09
Apptly Health Technologies Corp.
ESVNF
Stockpicker

Video analysis: ESVNF

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: ESVNF

Apptly Commences Trading on the OTCQB and Becomes DTC Eligible

newsfilecorp.com · 2 Sep 2026

Apptly Commences Trading on the OTCQB and Becomes DTC Eligible

Vancouver, British Columbia--(Newsfile Corp. - September 2, 2026) - Apptly Health Technologies Corp. (CSE: APPT) (OTCQB: ESVNF) (the "Company" or "Apptly"), operator of the UberDoc direct-pay healthcare marketplace, today announced that it has been approved to trade on the OTCQB Venture Market ("OTCQB") in the United States under the symbol "ESVNF", effective September 2, 2026. The Company also confirms that its common shares are eligible for electronic clearing and settlement through the Depository Trust Company ("DTC").

UberDoc Health Technologies Appoints Lemonaid Health Co-Founder Paul Johnson to Advisory Board and Changes Name to Apptly Health Technologies Corp.

newsfilecorp.com · 23 Jun 2026

UberDoc Health Technologies Appoints Lemonaid Health Co-Founder Paul Johnson to Advisory Board and Changes Name to Apptly Health Technologies Corp.

Builder of the U.S. direct-to-consumer telehealth category joins the physician-founded, surgeon-led marketplace as it scales nationwide direct-pay access Advisor Appointment Vancouver, British Columbia--(Newsfile Corp. - June 23, 2026) - Apptly Health Technologies Corp. (CSE: APPT) (FSE: 4KL0) (the "Company" or "Apptly"), operator of the UberDoc direct-pay healthcare marketplace, is pleased to announce the appointment of Paul Johnson to its advisory board (the "Advisory Board"). Johnson co-founded Lemonaid Health, the first national direct-to-consumer telehealth service in the United States, and led it as Chief Executive Officer through its US$400 million sale to 23andMe in 2021.

UBERDOC Health Technologies Corp. Announces Proposed Corporate Name Change to Apptly Health Technologies Corp.

newsfilecorp.com · 18 Jun 2026

UBERDOC Health Technologies Corp. Announces Proposed Corporate Name Change to Apptly Health Technologies Corp.

Rebrand reflects the Company's evolution into a marketplace for direct-pay specialty care, built on the UberDoc network and a single principle: the appropriate care, at the appropriate price, by the appropriate physician. Boston, Massachusetts--(Newsfile Corp. - June 18, 2026) - UBERDOC Health Technologies Corp. (CSE: APPT) (FSE: 4KL0) (the "Company") is pleased to announce its intention to change its corporate name to Apptly Health Technologies Corp. ("Apptly").

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.